"Payviders" are responsible for the cost of avoidable readmissions and emergency room visits, but they lose sight of patients once they go home.
News|Articles|December 29, 2021
Best Read Articles on Formularies and Formulary Changes in 2021
Author(s)Briana Contreras
Our best read stories about formularies include news about 2022 formularies from CVS Caremark and Express Scripts.
Advertisement
Express Scripts Releases List of 2022 Formulary Exclusions
Four products on the preferred list this year will be excluded next year.
Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
CVS Caremark Announces Formulary for 2022
CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.
Cigna Releases Formulary Changes for 2022
Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Advertisement
Related to this article
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.
Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.
2
Vaccine schedule overhaul could put coverage at risk, state official says
3
The payvider blind spot: When clinical visibility ends but financial risk continues
4
Bronchiectasis is more common in the U.S. than a decade ago, study finds
5